Loading
companiesCompany
Celldex Therapeutics
Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.
Overview
Glembatumumab vedotin (CDX-011, GPNMB-directed MMAE ADC) did not meet its primary endpoint in the METRIC trial in GPNMB-overexpressing metastatic TNBC (2018). Celldex's lead asset is now barzolvolimab, an anti-KIT antibody in phase 3 for chronic urticaria; its oncology footprint is historical but instructive for ADC target selection.
Headquarters
Hampton, NJ, US
Scorecard
All companies#489of 1244 companies, score 4
- targets +2
- modalities +2
- registry trials +3
- failures -3
0 approved, 0 in phase 3, 0 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Biotech · CLDX
Stage
Public
Website
NegativePeptide vaccine (EGFRvIII)
Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGFRvIII at recurrence, a lesson in antigen escape.
Similar pages
- TermEGFRvIII
Shares Rindopepimut, ACT IV.
- TreatmentTrastuzumab duocarmazine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- TrialKRISTINE
Shares Antibody-drug conjugate (ADC) and the tag failure.
- TreatmentTusamitamab ravtansine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- TreatmentIniparib
Shares Triple-negative breast cancer (TNBC) and the tag failure.
- TreatmentRovalpituzumab tesirine
Shares Antibody-drug conjugate (ADC) and the tag failure.
- TrialIMpassion131
Shares Triple-negative breast cancer (TNBC) and the tag failure.
- TermPlacebo
cancers
fronts
technologies
targets
drugs
NegativePeptide vaccine (EGFRvIII)